Navigation Links
Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
Date:5/6/2008

SUNNYVALE, Calif., May 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) announced today that the Company will present at the following investor conferences:

-- The Robert W. Baird Growth Stock Conference on May 13 at 12:15 p.m. EDT

at The Four Seasons Hotel in Chicago

-- The Bank of America Healthcare Conference on May 14 at 3:40 p.m. EDT at

The Four Seasons Hotel in Las Vegas

John Bishop, Chief Executive Officer, and Andrew Miller, Senior Vice President, Chief Financial Officer, will provide a corporate overview at each conference.

Live webcasts, along with accompanying presentation slides, may be accessed on Cepheid's Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentations will be available for 90 days following the live events.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080129/LATU101LOGO)


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
2. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
3. Cepheid Reports Fourth Quarter and Full Year 2007 Results
4. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
5. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
6. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
7. Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System
8. Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference
9. Cepheid to Present at William Blair Small-Cap Growth Stock Conference
10. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
11. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):